Paul L R Mitchell
Olivia Newton-John Cancer Wellness & Research Centre · 119 works · 3,223 citations · h-index 27
Top works
- Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
- A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
- High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies
- Treatment of nondysgerminomatous ovarian germ cell tumors
- Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors
- Health-Related Quality of Life and Utility in Patients with Advanced Non–Small-Cell Lung Cancer: A Prospective Cross-Sectional Patient Survey in a Real-World Setting
- Clinical Practice Guidelines for the Prevention, Diagnosis and Management of Lung Cancer
- The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma
- Differences in cancer survival by sex: a population-based study using cancer registry data
- Positron emission tomography scanning in the assessment of patients with lymphoma
- Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
- Lung cancer in Victoria: are we making progress?
- High Impact of 18F-FDG-PET on Management and Prognostic Stratification of Newly Diagnosed Small Cell Lung Cancer
- Rarity ofAKT1andAKT3E17K mutations in squamous cell carcinoma of lung
- START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer.
- CheckMate 384: Phase IIIb/IV trial of nivolumab (nivo) 480 mg Q4W versus 240 mg Q2W after ≤ 12 months of nivo in previously treated advanced NSCLC.
- Prognostic Value of 18F-FDG PET/CT in Patients with Malignant Pleural Mesothelioma
- A Malignant Neoplasm From the Jejunum With a MALAT1-GLI1 Fusion and 26-Year Survival History
- Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination
- The Role of Cancer-Testis Antigens as Predictive and Prognostic Markers in Non-Small Cell Lung Cancer